PubMed
Ipamorelin, a new growth hormone-releasing peptide
Johansen PB, Nowak J, Skjaerbaek C, et al. Eur J Endocrinol. 2001
Compare
Ipamorelin vs Semaglutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Ipamorelin
102 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
236
Sleep
236
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
2
Headache
2
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
0.05–0.1 mg
12
0.1–0.2 mg
63
0.2–0.4 mg
137
0.4–0.6 mg
22
5+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 98% said they felt similar to their last entry, 2% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 44 repeat reporters
Semaglutide
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 96% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
122
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
117
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
32
0.2–0.4 mg
5
0.4–0.6 mg
4
0.6–1 mg
9
1–2 mg
33
2–3 mg
34
5+ mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 23 repeat reporters
Sources (13)
Published sources linked on the Ipamorelin and Semaglutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
Ipamorelin growth hormone studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. European journal of endocrinology. 1998
- Wiki study page →Source
PubMed
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
Lu Z, Ngan MP, Liu JYH, et al. Physiology & behavior. 2024
- Wiki study page →Source
FDA Drug Label
WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo Nordisk. FDA Drug Label. 2021
- Wiki study page →Source
FDA Drug Label
OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo Nordisk. FDA Drug Label. 2017
- Wiki study page →Source
PubMed
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021
- Wiki study page →Source
ClinicalTrials.gov
Semaglutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. N Engl J Med. 2022
- Wiki study page →Source
PubMed
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. N Engl J Med. 2023
- Wiki study page →Source
PubMed
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Wharton S, Calanna S, Davies M, et al. Diabetes Obes Metab. 2022
- Wiki study page →Source
PubMed
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine. 2023